Descripción del proyecto
Centrar la atención en subpoblaciones preexistentes de células cancerosas de ovario farmacorresistentes
El cáncer ovárico es el quinto tipo de cáncer con más mortalidad en Europa. La quimioterapia convencional es eficaz a la hora de eliminar las masas tumorales, pero la mayoría de las pacientes diagnosticadas con cáncer ovárico avanzado fallecen tras el surgimiento de nuevas lesiones generadas a partir de pequeñas subpoblaciones de células supervivientes farmacorresistentes. El proyecto RESIST3D, financiado con fondos europeos, está desarrollando nuevos rumbos en la oncología de precisión al centrar su atención en pequeñas subpoblaciones de células farmacorresistentes en lugar de en la masa del tumor. La investigación utiliza organoides tridimensionales de cáncer ovárico derivados de pacientes para descubrir nuevas estrategias de erradicación de las células cancerosas farmacorresistentes. Los modelos para la elaboración de perfiles de respuesta farmacológica ayudarán en la identificación del tratamiento de erradicación de las células farmacorresistentes preexistentes que se aplicará en combinación con la quimioterapia convencional.
Objetivo
Ovarian cancer is the fifth most deadly cancer type among women in Europe. Despite the fact that standard chemotherapy is usually effective in eliminating bulk tumour mass, thereby inducing remission, most patients diagnosed with advanced ovarian cancer die from the disease, as relapsed lesions emerge from small subpopulations of surviving drug-resistant cells.
Precision medicine aims to improve cancer care through tailoring individualized therapies based on genomic or functional profiling of human cancers. However, as these approaches are usually performed on bulk tumour cells, the small pre-existing drug-resistant cell subpopulations remain untargeted.
In the RESIST3D project, I will utilize ovarian cancer organoids – a patient-derived, three-dimensional cell cultures – to search for new strategies to eradicate drug-resistant cancer cells. I will use two organoid models developed for the same patient – one model derived from tumour material taken before chemotherapeutic treatment and one from a post-treatment sample, typically enriched in drug-resistant cells. I will further enrich the organoids in quiescent, drug-resistant cells by maintaining them in physiologic-like culture medium. I will then apply the models for drug-response profiling in order to identify agents that eradicate pre-existing drug-resistant cells, which could be combined with standard chemotherapy. Finally, I will assess whether the selected combinations prevent relapses in patient-derived xenograft mouse models.
RESIST3D sets a new direction in precision cancer medicine, as it focuses on targeting small pre-existing subpopulations of drug-resistant cells rather than bulk tumour mass. Through combining organoid model, paired samples for each patient and physiologic culture conditions, I expect to identify new ways to target drug-resistant ovarian cancer cells. Moreover, RESIST3D will provide me with new research expertise and a scientific network that will enhance my research career.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
1165 Kobenhavn
Dinamarca